

09 Apr 2023 | News

# Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: GSK deal strengthens its infectious disease pipeline; an analysis of the first drugs subject to US Medicare price negotiations; Roche partnering head talks about strategy; promising early Alzheimer's results for Biogen's tau drug; and what India needs to become a world-class innovation hub.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 7 April 2023, including: [GSK plc](#) deal strengthens its infectious disease pipeline; an analysis of the first drugs subject to US Medicare price negotiations; [Roche Holding AG](#) partnering head talks about strategy; promising early Alzheimer's results for [Biogen, Inc.](#)'s tau drug; and what India needs to become a world-class innovation hub.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[GSK Boosts Its Infectious Disease Portfolio With Brexafemme License](#)" - Scrip, 30 Mar, 2023.)

(Also see "[First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands](#)" - Scrip, 30 Mar, 2023.)

(Also see "[\*Roche Continues To Cast Its Collaborations Net Wide\*](#)" - Scrip, 30 Mar, 2023.)

(Also see "[\*Biogen Drug Sends Tau Into Reverse: An Alzheimer's Breakthrough In The Making?\*](#)" - Scrip, 3 Apr, 2023.)

(Also see "[\*Whiteboarding Ideas From Novartis, Novo To Address India's Elephants In The Room, 'On Streets'\*](#)" - Scrip, 31 Mar, 2023.)

[Click here to explore this interactive content online](#) ✨